Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer

(2020) Anna K. Blakney et al.   ACS Nano

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

(2020) Pedro M Folegatti et al.   LANCET INFECTIOUS DISEASES

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

(2020) Noe B. Mercado et al.   NATURE

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

(2020) Neeltje van Doremalen et al.   NATURE

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

(2020) Paul F. McKay et al.   Nature Communications

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

(2020) Simon P. Graham et al.   npj Vaccines

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

(2020) Carolyn Rydyznski Moderbacher et al.   CELL

Vaccines for COVID‐19

(2020) J. S. Tregoning et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

(2020) Wen Shi Lee et al.   Nature Microbiology

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

(2020) Katie J. Ewer et al.   NATURE MEDICINE

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

(2020) Jordan R. Barrett et al.   NATURE MEDICINE

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal

(2018) Navin Venkatraman et al.   JOURNAL OF INFECTIOUS DISEASES

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens

(2017) Katie Ewer et al.   Human Vaccines & Immunotherapeutics

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

(2014) Sheng-Fan Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens

(2013) Richard D Antrobus et al.   MOLECULAR THERAPY

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

(2012) Chien-Te Tseng et al.   PLoS One